Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3200

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Maridebart cafraglutide
DRUG: Placebo

Sponsor

Amgen